Triglycerides, Medium Chain; Triglycerides, Long Chain
Betaquik: dietary management of conditions requiring a source of medium chain triglycerides (chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders) or ketogenic diet (intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency). Carbzero: ketogenic diet (intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency).
From the public summary
6.1 The PBAC decided not to recommend amending the maximum quantity of cartons per script from two to three of both Betaquik® and Carbzero®, for the dietary management of conditions requiring a source of medium chain triglycerides and for patients who require a ketogenic diet respectively.PSD · Nov 2017
6.2 The PBAC also noted the change to container size for Betaquik® and Carbzero® from 250 mL to 225 mL, and the change in number of containers per carton from 18 to 15.PSD · Nov 2017
Cost-effectiveness
Cost-minimisation analysis presented; no traditional ICER calculated. This is a minor submission for a reformulation/repackaging of existing listed products.
The PBAC considered that the increase in volume per script would result in a higher dispensed maximum quantity per script, and potentially higher costs to the PBS. PBAC · 2017
Decision context
PopulationPatients requiring dietary management of conditions requiring a source of medium chain triglycerides (chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders) or ketogenic diet (intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency).
Why it was knocked back
- Increase in maximum quantity per script not clinically appropriate; would increase total volume per script from 9 L to 10.125 L resulting in higher PBS costs; NPWP did not support the proposed amendment
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2017 | Not recommended | — | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
There PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC specifies defined clinical conditions (chylous ascites, cystic fibrosis, intractable seizures, etc.) versus TGA's broad 'medical purposes' classification.